Trial · NCT02784535

Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

NCT02784535, Phase 2, Completed, Vanderbilt University Medical Center; results first posted 2022-09-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Norepinephrine Transporter Blockade, Autonomic Failure (NETAF). Trials, record NCT02784535. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02784535

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
NCT number: NCT02784535
Status: Completed
Phases: Phase 2
Enrollment: 48 participants, actual
Lead sponsor: Vanderbilt University Medical Center
Conditions: Neurogenic Orthostatic Hypotension
Interventions: Atomoxetine, Placebo
First posted: 2016-05-27
Last updated: 2023-09-13
Results first posted: 2022-09-16

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	week 0 to week 4	The Orthostatic Hypotension Questionnaire (OHQ) , patient-reported assessment tool consisting of the OH Symptom Assessment (OHSA), OH Daily Activity Scale (OHDAS). The composite score is composed of 10 individual items: 6 items measure specific symptoms , the Orthostatic Hypotension Symptom Assessment (OHSA), and 4 items measure the impact of those symptoms on a patient daily activities, the Orthostatic Hypotension Daily Activity Scale (OHDAS). This scales helps to measure the impact of orthostatic symptoms on daily. Scale is between 0-10: where "0" is minimum Orthostatic symptoms and "10" is the maximum / worse possible severity of the symptoms. All items are scored 0 through 10 (higher scores = more impact) and summed into the respective total scores. The OHSA and OHDAS subscales averaged to compute the OHQ composite score.
Secondary	Change in Blood Pressure	Baseline to 4 weeks	Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) (measured in mm of Hg) , is recorded after 10 mins of standing. The changes SBP and DBP are compared from baseline, post drug (4 weeks)
Secondary	Change in Heart Rate (HR)	Baseline and at 4 weeks	HR is compared to baseline after 10 mins of standing. The difference increase in Heart rate from baseline, post drug at 4 weeks

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	week 0 to week 4	Score on a scale	MEAN
SECONDARY	Change in Blood Pressure	Baseline to 4 weeks	mm of Hg	MEAN
SECONDARY	Change in Heart Rate (HR)	Baseline and at 4 weeks	Beats per minute	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	Placebo	OHQ composite score at Baseline	4.61	Standard Deviation 2.16	Score on a scale
Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	Atomoxetin	OHQ composite score at Baseline	4.17	Standard Deviation 2.29	Score on a scale
Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	Placebo	OHQ composite score at 4weeks	3.35	Standard Deviation 1.98	Score on a scale
Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	Atomoxetin	OHQ composite score at 4weeks	3.5	Standard Deviation 2.25	Score on a scale
Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	Placebo	Difference in OHQ composite score at 4 weeks	-0.58	Standard Deviation 2.39	Score on a scale
Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	Atomoxetin	Difference in OHQ composite score at 4 weeks	-0.5	Standard Deviation 1.58	Score on a scale
Change in Blood Pressure	Placebo	difference increase in SBP; post drug 4 weeks; standing for 10 mins	3.88	Standard Deviation 19.83	mm of Hg
Change in Blood Pressure	Atomoxetine	difference increase in SBP; post drug 4 weeks; standing for 10 mins	-2.44	Standard Deviation 23.54	mm of Hg
Change in Blood Pressure	Placebo	DBP;post drug; standing 10 mins at 4 weeks	-3.06	Standard Deviation 15.85	mm of Hg
Change in Blood Pressure	Atomoxetine	DBP;post drug; standing 10 mins at 4 weeks	-0.94	Standard Deviation 15.6	mm of Hg

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Atomoxetine Then Placebo	20
Overall Study	STARTED	Placebo Then Atomoxetine	20
Overall Study	COMPLETED	Atomoxetine Then Placebo	19
Overall Study	COMPLETED	Placebo Then Atomoxetine	18
Overall Study	NOT COMPLETED	Atomoxetine Then Placebo	1
Overall Study	NOT COMPLETED	Placebo Then Atomoxetine	2

Source ClinicalTrials.gov

Adverse events39

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headache	Nervous system disorders	Dose Optimization Phase	0	48
other	Headache	Nervous system disorders	Placebo	3	40
other	Headache	Nervous system disorders	Atomoxetine	1	40
other	Insomnia	Psychiatric disorders	Dose Optimization Phase	0	48
other	Insomnia	Psychiatric disorders	Placebo	1	40
other	Insomnia	Psychiatric disorders	Atomoxetine	1	40
other	Reflux esophagitis	Gastrointestinal disorders	Dose Optimization Phase	0	48
other	Reflux esophagitis	Gastrointestinal disorders	Placebo	1	40
other	Reflux esophagitis	Gastrointestinal disorders	Atomoxetine	2	40
other	Urinary tract infection	Renal and urinary disorders	Dose Optimization Phase	0	48

1 to 10 of 39Source ClinicalTrials.gov

See all 39 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dose Optimization Phase	0	48
Total, all-cause mortality	Placebo	0	40
Total, all-cause mortality	Atomoxetine	1	40
Total, other adverse events	Dose Optimization Phase	1	48
Total, other adverse events	Placebo	13	40
Total, other adverse events	Atomoxetine	13	40
Total, serious adverse events	Dose Optimization Phase	0	48
Total, serious adverse events	Placebo	1	40
Total, serious adverse events	Atomoxetine	2	40

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
17515448	BACKGROUND	PubMed
25185131	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02784535

GET https://conductscience.org/api/trials/v1/NCT02784535/events?page=2

API reference For AI assistants